XML 25 R18.htm IDEA: XBRL DOCUMENT v3.25.4
Intangible Assets
 6 Months Ended
Dec. 31, 2025
Intangible Assets [Abstract]  
Intangible Assets

Note 8. Intangible Assets

Intellectual Property

The acquired intellectual property relates to cancer stem cell technology and is carried at its cost on the date of acquisition, less accumulated amortization and impairment charges. There was no impairment identified by the Company at December 31, 2025.

 

Cancer Stem
Cell Technology

 

Carrying amount at June 30, 2025

 

$

4,804,791

 

Amortization expense

 

 

(331,365

)

Carrying amount at December 31, 2025

 

$

4,473,426

 

 

 

 

 

Carrying amount at June 30, 2024

 

$

5,467,522

 

Amortization expense

 

 

(331,365

)

Carrying amount at December 31, 2024

 

$

5,136,157

 

Acquired intellectual property with a finite life is recognized as an asset at cost and amortized on a straight-line basis over its estimated useful life of 20 years. There is currently no internally generated intellectual property that has been capitalized.